The Patent Fortress: Senator Hassan Challenges Merck’s Grip on Keytruda
Senator Maggie Hassan (D-N.H.) has formally challenged Merck & Co. over its aggressive patent strategies regarding Keytruda, the pharmaceutical giant’s blockbuster cancer immunotherapy. As the ranking member of the Senate Finance Subcommittee on Health Care, Hassan is demanding transparency regarding the company’s use of secondary patents to extend market exclusivity.
The Mechanics of Evergreening and Market Delay
Hassan’s inquiry specifically targets the transition from the long-standing intravenous (IV) version of the drug to a newer, injectable formulation.
As noted in the Cancer Calculus investigation by the International Consortium of Investigative Journalists, these strategies are designed to provide a financial runway that could potentially delay market competition until the 2030s.
The Regulatory and Economic Ripple Effects
The Human Cost of Pharmaceutical Strategy
Patients are often left to navigate a system where the price of a drug like Keytruda—which is essential for treating various forms of melanoma, lung cancer, and other malignancies—remains consistently high, even as the drug approaches its second decade on the market.
Looking Ahead: The Path to Reform
We want to hear your perspective on this. Do you believe that current patent laws provide a fair balance between rewarding innovation and ensuring patient access, or is it time for a radical overhaul of the system? Let’s discuss the balance of power in modern medicine in the comments below.
